We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost.13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA...
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can...
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can...
We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate ...
BACKGROUND: We have previously shown that an HIV vaccine regimen including three doses of HIV-modifi...
PMID: 21865377Attenuated poxvirus vectors expressing HIV-1 antigens are considered promising HIV/AID...
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
BACKGROUND:A vaccine against HIV is widely considered the most effective and sustainable way of redu...
A vaccine against HIV is widely considered the most effective and sustainable way of reducing new in...
BackgroundHVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine r...
Objectives: The safety, immunogenicity, impact on the latent reservoir and rebound of viral load aft...
BACKGROUND: Durability of vaccine-elicited immune responses is one of the key determinants for vacci...
Affordable therapeutic strategies that induce sustained control of human immunodeficiency virus type...
<div><h3>Study Design</h3><p>A randomized, double-blind, placebo controlled phase I trial.</p> <h3>M...
INTRODUCTION: Vaccines may be key components of a curative strategy for HIV-1. We investigated wheth...
Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can...
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can...
We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate ...
BACKGROUND: We have previously shown that an HIV vaccine regimen including three doses of HIV-modifi...
PMID: 21865377Attenuated poxvirus vectors expressing HIV-1 antigens are considered promising HIV/AID...
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
BACKGROUND:A vaccine against HIV is widely considered the most effective and sustainable way of redu...
A vaccine against HIV is widely considered the most effective and sustainable way of reducing new in...
BackgroundHVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine r...
Objectives: The safety, immunogenicity, impact on the latent reservoir and rebound of viral load aft...
BACKGROUND: Durability of vaccine-elicited immune responses is one of the key determinants for vacci...
Affordable therapeutic strategies that induce sustained control of human immunodeficiency virus type...
<div><h3>Study Design</h3><p>A randomized, double-blind, placebo controlled phase I trial.</p> <h3>M...
INTRODUCTION: Vaccines may be key components of a curative strategy for HIV-1. We investigated wheth...
Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can...
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can...
We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate ...